These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21194438)

  • 1. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
    Gruenwald V; Beutel G; Schuch-Jantsch S; Reuter C; Ivanyi P; Ganser A; Haubitz M
    BMC Cancer; 2010 Dec; 10():695. PubMed ID: 21194438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.
    Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A
    Ann Oncol; 2015 Jun; 26(6):1118-1123. PubMed ID: 25701452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
    Calvani N; Morelli F; Chiuri V; Gnoni A; Scavelli C; Fedele P; Orlando L; Maiello E; Lorusso V; Cinieri S
    Med Oncol; 2013; 30(2):578. PubMed ID: 23613183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
    J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
    Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ
    Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
    Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
    Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA
    J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
    Farace F; Gross-Goupil M; Tournay E; Taylor M; Vimond N; Jacques N; Billiot F; Mauguen A; Hill C; Escudier B
    Br J Cancer; 2011 Mar; 104(7):1144-50. PubMed ID: 21386843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
    J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
    Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
    Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
    BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.